Breath biopsy testing market to reach $4.9 billion by 2030

The breath biopsy testing market is projected to grow from $3.43 billion in 2025 to $3.69 billion in 2026, then reach $4.9 billion by 2030, according to a new Business Research Company report. The forecast points to rising demand for non-invasive diagnostics, more respiratory disease cases and broader use of AI and portable testing devices.

Why it matters: - Breath biopsy testing is moving from a niche diagnostic concept toward wider clinical use as healthcare systems look for faster, non-invasive ways to detect disease. - The market outlook signals growing commercial demand for tools that can support early diagnosis, especially for respiratory conditions. - The report’s forecast suggests the category could become more important in routine screening, personalized medicine and portable diagnostics.

What happened: - The Business Research Company released a new report on the global breath biopsy testing market covering 2026 through 2035. - The market is projected to rise from $3.43 billion in 2025 to $3.69 billion in 2026, a 7.7% compound annual growth rate. - The report forecasts the market will reach $4.9 billion by 2030, with a 7.3% CAGR over the period. - North America led the market in 2025. - Asia-Pacific is expected to grow the fastest over the forecast period. - The report includes coverage of South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated graphics and tables. - More information is available in the full report. - A free sample of the report is also available.

The details: - Breath biopsy testing analyzes chemical compounds in exhaled breath to help detect and diagnose diseases. - The technology looks for disease-related chemical markers and volatile organic compounds, or VOCs. - The market’s recent growth is tied to rising demand for non-invasive diagnostic tools, more clinical research on breath biomarkers, better sensors and spectroscopy, expanded diagnostic laboratory services and patient preference for painless testing. - The forecast to 2030 is supported by broader use of breath-based diagnostics in routine health screenings. - The report points to higher investment in AI-powered diagnostic platforms as another growth driver. - Personalized medicine applications are also expected to add demand. - Portable diagnostic devices are expected to gain more use. - Stronger regulatory support for non-invasive testing methods is part of the outlook. - Emerging trends include VOC-based disease detection, AI-driven breath analysis, portable breath sampling and a stronger focus on early disease detection. - The rising incidence of respiratory diseases is a major driver of demand. - Environmental pollution, smoking and chronic illnesses such as asthma and chronic obstructive pulmonary disease are contributing to that burden. - In May 2025, CDC data showed COPD was the fifth leading cause of death in the U.S. in 2023, with 141,733 fatalities. - The CDC also reported an age-adjusted diagnosed COPD prevalence of 3.8% among U.S. adults in 2023.

Between the lines: - The market forecast reflects a broader shift in diagnostics toward lower-burden testing that can be deployed outside traditional invasive workflows. - AI and portable devices stand out because they can make breath testing more scalable and easier to use in everyday care. - The emphasis on respiratory disease suggests the strongest near-term commercial use case remains lung and airway conditions. - North America’s lead likely reflects better infrastructure and faster adoption of new diagnostics, while Asia-Pacific’s growth points to unmet need and expanding healthcare investment.

What's next: - The market is expected to keep expanding through 2030 as non-invasive diagnostics become more widely adopted. - Watch for more investment in breath-analysis software, portable sampling systems and VOC detection platforms. - Regulatory and clinical validation will likely shape how quickly breath biopsy testing moves into broader routine use. - The Business Research Company said its 2026 reports now include expanded strategic intelligence and market analysis tools.